about
sameAs
Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine developmentKinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvantEngineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticlesA comparison of temporal trends in United States autism prevalence to trends in suspected environmental factorsAluminum-induced entropy in biological systems: implications for neurological diseaseComparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responsesAllergic Responses Induced by the Immunomodulatory Effects of Nanomaterials upon Skin ExposureNegatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.Highly sensitive and selective colorimetric and off-on fluorescent reversible chemosensors for Al³⁺ based on the rhodamine fluorophore.Aluminum hydroxide injections lead to motor deficits and motor neuron degenerationXanthan gum as an adjuvant in a subunit vaccine preparation against leptospirosis.Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxicationMultiparameter telemetry as a sensitive screening method to detect vaccine reactogenicity in miceImmune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220.Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicleHighly effective generic adjuvant systems for orphan or poverty-related vaccinesA polymer/oil based nanovaccine as a single-dose immunization approach.A coumarin-based "turn-on" fluorescent sensor for the determination of Al3+: single crystal X-ray structure and cell staining properties.Aluminium in Allergies and Allergen immunotherapy.Use of Phage Display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomesAdjuvants for vaccines to drugs of abuse and addiction.Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.A New Fluorescence Turn-On Probe for Aluminum(III) with High Selectivity and Sensitivity, and its Application to Bioimaging.Lipid nanocapsule as vaccine carriers for his-tagged proteins: evaluation of antigen-specific immune responses to HIV I His-Gag p41 and systemic inflammatory responsesRapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity.Bacterial-metal interactions: the potential role of aluminum and other trace elements in the etiology of Crohn's disease.Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphateAdsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challengeConsiderable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c miceSafety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneImmunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infectionHuman health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivoPromising particle-based vaccines in cancer therapy.Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA).Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity
P2860
Q21284959-38567D28-C364-4042-AAB2-CEE4978D2289Q24802323-FB4FBD63-FF2B-4CA9-95A5-362D5045B8EFQ28394668-B7ACB93D-E384-4608-98BD-2A85691712A8Q28394965-B7D90995-431B-4B0D-A56E-6DC2A9EA6338Q28396107-EDBF28ED-1671-4247-B618-C61ADF5EE735Q28507643-D9EE4AC6-7286-44A8-8B6D-D333C2907A9FQ29248341-D8340E05-B049-4FF0-AB65-85D7BE1BDCD3Q30361416-A4D6758C-2C3F-4535-9BCE-C9FAC903F142Q30937779-2409C193-FC2F-4E1A-B96E-0E7E772D4966Q33644364-7D371B87-6031-4C43-9F08-74FC56A14F63Q33661011-A0FDE21E-C534-4295-AE85-F4562747441BQ33728320-882EC65D-0551-4F19-B6BD-25AACD3E5581Q34012394-D267DA90-6895-4C5C-BE8D-36C6A4913FF8Q34140252-63D33ABA-7F03-4095-91B8-3FA47C9CC881Q34147433-CCE73CA1-54AA-4892-9E1E-4506D7A13EE9Q34194609-FD74A064-09EA-4A1B-88E8-F630784D5518Q34271517-B8C67913-8ED4-4934-A8A1-B837DC9B3196Q34307955-DF41AAE8-D305-4D9D-B1BC-0DEE3284C86CQ34685874-F1801533-06CC-468B-ABB0-8D45219E9A40Q34752170-717509C3-91C8-4564-9EE9-7486B8DE0391Q35142804-4CCC6F9B-3A8F-4FA7-9043-BD4DB7D718CAQ35156323-8A48FADB-D2E7-4ECD-B31E-683270232631Q35493923-C172FD2E-C504-412D-8438-D5E95C8DCF6AQ35666215-36D91090-CB54-4385-8F35-C5655F33A64AQ35738509-9743C468-1D6F-4819-9450-B6D8EFFC8EEFQ35740218-CA78C5EA-2DB4-49A7-94AA-CB5ECB1B3479Q35983565-3C115DD1-40F7-456A-98B7-B7443323AFB8Q35997121-C7E92F14-D45A-4F86-B0FF-44E677B0D544Q36256394-7C9DA990-C53D-41F0-9392-7527EE07AB04Q36487366-D33C4186-76AC-4210-ABBD-3451B88FB379Q36497665-8E33826D-9B04-497C-84CC-C579A5C2CA21Q36500189-F791EAEF-EED6-4CBC-BB44-D3876AF4546BQ36931790-ABE2A11A-9C95-471A-A625-CF823D20FD55Q37033007-57739254-F412-4DB2-8C23-7D544A974BA4Q37034318-70EF3B75-D8A7-4CDA-BCA1-14063FEA7D26Q37098801-86C07ACA-C16F-4DBF-8364-E4F47AFBF706Q37118993-E5CFE4FE-41D9-497B-B3CD-132311B1C527Q37259642-0AF48C0C-D80E-4DCF-9E92-5400B1CFE520Q37265775-5DDB528E-AFD3-4DB4-AAF7-3F7D68518DCFQ37280340-F6FC4095-7D3B-4429-B3C2-90AA18F578A1
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Aluminum salts in vaccines--US perspective
@ast
Aluminum salts in vaccines--US perspective
@en
Aluminum salts in vaccines--US perspective
@nl
type
label
Aluminum salts in vaccines--US perspective
@ast
Aluminum salts in vaccines--US perspective
@en
Aluminum salts in vaccines--US perspective
@nl
prefLabel
Aluminum salts in vaccines--US perspective
@ast
Aluminum salts in vaccines--US perspective
@en
Aluminum salts in vaccines--US perspective
@nl
P2093
P3181
P1433
P1476
Aluminum salts in vaccines--US perspective
@en
P2093
Norman W Baylor
Paul Richman
William Egan
P304
P3181
P356
10.1016/S0264-410X(02)00166-4
P407
P478
20 Suppl 3
P577
2002-05-31T00:00:00Z